The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein

American Journal of Physiology - Cell Physiology

Volumn 301, Issue 5, 2011, Pages

  Gonçalves, Pedro ^a   Gregório, Inês ^a   Martel, Fátima ^a  

^a University of Porto   (Portugal)

Author keywords

Anticarcinogenic effect; Butyrate efflux; Colorectal cancer; IEC 6 cells

Indexed keywords

ALKALINE PHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; BUTYRIC ACID; CARBON 14; LACTATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; SULFORHODAMINE B; TRITIUM;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CACO-2 CELLS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RATS;

RATTUS;

EID: 80054897988     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00146.2011     Document Type: Article

References (74)

1. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GH, Schinkel AH. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1: 417-425, 2002.
2. Bergmeyer HU, Bernt E. Lactate dehydrogenase. In: Methods in Enzymatic Analysis, edited by Bergmeyer HU. New York: Academic, 1974, p. 574-579.
3. Bradford MM. A rapid method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
4. Bras-Gonçalves RA, Pocard M, Formento JL, Poirson-Bichat F, De Pinieux G, Pandrea I, Arvelo F, Ronco G, Villa P, Coquelle A, Milano G, Lesuffleur T, Dutrillaux B, Poupon MF. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology 120: 874-88, 2001.
5. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63: 4048-4054, 2003.
6. Cho HJ, Kim SY, Kim KH, Kang WK, Kim JI, Oh ST, Kim JS, An CH. The combination effect of sodium butyrate and 5-Aza-2'-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines. World J Surg Oncol 7: 49, 2009.
7. Cuff M, Dyer J, Jones M, Shirazi-Beechey S. The human colonic monocarboxylate transporter Isoform 1: its potential importance to colonic tissue homeostasis. Gastroenterology 128: 676-686, 2005.
8. Cui D, Morris ME. The drug of abuse gamma-hydroxybutyrate is a substrate for sodium-coupled monocarboxylate transporter (SMCT) 1 (SLC5A8): characterization of SMCT-mediated uptake and inhibition. Drug Metab Dispos 37: 1404-1410, 2009.
9. Cummings JH, Pomare EW, Branch WJ, Naylor CPE, MacFarlane GT. Short chain fatty acids in human large intestine, portal, hepatic, and venous blood. Gut 28: 1221-1227, 1987.
10. Cummins CL, Mangravite LM, Benet LZ. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm Res 18: 1102-1109, 2001.
11. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 133, Suppl 7: 2485S-2493S, 2004.
12. de Haan JB, Gevers W, Parker MI. Effects of sodium butyrate on the synthesis and methylation of DNA in normal cells and their transformed counterparts. Cancer Res 46: 713-716, 1986.
13. Deeken John F, Robey Rob Zhan Zhirong Bates Susan E. ABCG2 expression, function and a SNP variant in the NCI drug screen cell lines. AACR Meeting Abstracts 47: 144-145, 2006.
14. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86: 849-899, 2006.
15. Delie F, Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst 14: 221-286, 1997.
16. Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52: 1788-1795, 2003.
17. El-Khoury V, Breuzard G, Fourré N, Dufer J. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. Br J Cancer 97: 562-573, 2007.
18. Englund G, Rorsman F, Rönnblom A, Karlbom U, Lazorova L, Gråsjö J, Kindmark A, Artursson P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29: 269-277, 2006.
19. Fedier A, Dedes KJ, Imesch P, Von Bueren AO, Fink D. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol 31: 633-641, 2007.
20. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. TiPS 25: 423-429, 2004.
21. Fukushima K, Sasaki I, Takahashi K, Naito H, Ogawa H, Sato S, Matsuno S. Lipopolysaccharide exhibits synergistic enhancement of butyrate- induced and retinoic acid-mediated alkaline phosphatase activity on small intestinal epithelial cell line, IEC-6. Digestion 59: 683-688, 1998.
22. Gill RK, Saksena S, Alrefai WA, Sarwar Z, Goldstein JL, Carroll RE, Ramaswamy K, Dudeja PK. Expression and membrane localization of MCT isoforms along the length of the human intestine. Am J Physiol Cell Physiol 289: C846-C852, 2005.
23. Gill RK, Dudeja PK. A novel facet to consider for the effects of butyrate on its target cells. Focus on ''The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein.'' Am J Physiol Cell Physiol (August 10, 2011). doi:10.1152/ajpcell.00290.2011.
24. Gonçalves P, Araújo JR, Martel F. Characterization of butyrate uptake by non-transformed intestinal epithelial cell lines. J Membr Biol 240: 35-46, 2011.
25. Gonçalves P, Araújo JR, Pinho MJ, Martel F. In vitro studies on the inhibition of colon cancer by butyrate and polyphenolic compounds. Nutr Cancer 63: 282-294, 2011.
26. Gonçalves P, Araújo JR, Pinho MJ, Martel F. Modulation of butyrate transport in Caco-2 cells. Naunyn Schmiedebergs Arch Pharmacol 379: 325-336, 2009.
27. Gupta N, Martin PM, Miyauchi S, Ananth S, Herdman AV, Martindale RG, Podolsky R, Ganapathy V. Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem Biophys Res Commun 343: 571-577, 2006.
28. Gupta N, Martin PM, Prasad PD, Ganapathy V. SLC5A8 (SMCT1)- mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci 78: 2419-2425, 2006.
29. Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 70: 695-699, 2005.
30. Hague A, Elder DJ, Hicks DJ, Paraskeva C. Apoptosis in colorectal tumour cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J Cancer 60: 400-406, 1995.
31. Hallert C, Björck I, Nyman M, Pousette A, Grännö C, Svensson H. Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm Bowel Dis 9: 116-121, 2003.
32. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27: 104-119, 2008.
33. Hauswald S, Duque-Afonso J, Wagner MM, Schertl FM, Lübbert M, Peschel C, Keller U, Licht T. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 15: 3705-3715, 2009.
34. Heerdt BG, Houston MA, Augenlicht LH. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 54: 3288-3293, 1994.
35. Ho SB, Yan P, Dahiya R, Neuschwander-Tetri BA, Basbaum C, Kim YS. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance. J Cell Physiol 160: 213-226, 1994.
36. Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 279: 25527-25534, 2004.
37. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 61: 69-90, 2001.
38. Jin S, Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18: 4377-4384, 1998.
39. Kurtze I, Sonnemann J, Beck JF. KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. Oncol Rep 25: 1021-1029, 2011.
40. Lee JE, Willett WC, Fuchs CS, Smith-Warner SA, Wu K, et al. Folate intake and risk of colorectal cancer and adenoma: modification by time. Am J Clin Nutr 93: 817-825, 2011.
41. Li T, Ito K, Horie T. Transport of fluorescein methotrexate by multidrug resistance-associated protein 3 in IEC-6 cells. Am J Physiol Gastrointest Liver Physiol 285: G602-G610, 2003.
42. Louis M, Rosato RR, Battaglia E, Néguesque A, Lapotre A, Grant S, Bagrel D. Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells. Int J Oncol 26: 1569-1574, 2005.
43. Mariadason JM, Velcich A, Wilson AJ, Augenlicht LH, Gibson PR. Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology 120: 889-899, 2001.
44. Massart C, Poirier C, Fergelot P, Fardel O, Gibassier J. Effect of sodium butyrate on doxorubicin resistance and expression of multidrug resistance genes in thyroid carcinoma cells. Anticancer Drugs 16: 255-261, 2005.
45. Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Foss F, Rosen N, Fojo AT. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biol Chem 264: 18031-18040, 1989.
46. Morris ME, Felmlee MA. Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J 10: 311-321, 2008.
47. Morrow CS, Nakagawa M, Goldsmith ME, Madden MJ, Cowan KH. Reversible transcriptional activation of mdr1 by sodium butyrate treatment of human colon cancer cells. J Biol Chem 269: 10739-10746, 1994.
48. Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl 216: 132-148, 1996.
49. Negrão MR, Keating E, Faria A, Azevedo I, Martins MJ. Acute effect of tea, wine, beer, and polyphenols on ecto-alkaline phosphatase activity in human vascular smooth muscle cells. J Agric Food Chem 54: 4982-4988, 2006.
50. Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev 61: 26-33, 2009.
51. Oostendorp RL, Beijnen JH, Schellens JH. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev 35: 137-147, 2009.
52. Pesavento JJ, Yang H, Kelleher NL, Mizzen CA. Certain and progressive methylation of histone H4 at lysine 20 during the cell cycle. Mol Cell Biol 28: 468-486, 2008.
53. Pick A, Klinkhammer W, Wiese M. Specific inhibitors of the breast cancer resistance protein (BCRP). Chem Med Chem 5: 1498-505, 2010.
54. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60: 47-50, 2000.
55. Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 12: 1547-1555, 2006.
56. Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 21: 1-26, 2006.
57. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86: 1179-1236, 2006.
58. Scharlau D, Borowicki A, Habermann N, Hofmann T, Klenow S, Miene C, Munjal U, Stein K, Glei M. Mechanisms of primary cancer prevention by butyrate and other products formed during gut floramediated fermentation of dietary fibre. Mutat Res 682: 39-53, 2009.
59. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3-29, 2003.
60. Seithel A, Karlsson J, Hilgendorf C, Björquist A, Ungell AL. Variability in mRNA expression of ABC and SLC transporters in human intestinal cells: comparison between human segments and Caco2 cells. Eur J Pharm Sci 28: 291-299, 2006.
61. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45: 689-723, 2005.
62. Taipalensuu J, Törnblom H, Lindberg G, Einarsson C, Sjöqvist F, Melhus H, Garberg P, Sjöström B, Lundgren B, Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299: 164-170, 2001.
63. Tanaka Y, Slitt AL, Leazer TM, Maher JM, Klaassen CD. Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 326: 181-187, 2005.
64. To KK, Polgar O, Huff LM, Morisaki K, Bates SE. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 6: 151-64, 2008.
65. van de Water FM, Boleij JM, Peters JG, Russel FG, Masereeuw R. Characterization of P-glycoprotein and multidrug resistance proteins in rat kidney and intestinal cell lines. Eur J Pharm Sci 30: 36-44, 2007.
66. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63: 5538-5543, 2003.
67. Weaver GA, Tangel CT, Krause JA, Parfitt MM, Jenkins PL, Rader JM, et al. Acarbose enhances human colonic butyrate production. J Nutr 127: 717-723, 1997.
68. White NR, Mulligan P, King PJ, Sanderson IR. Sodium butyratemediated Sp3 acetylation represses human insulin-like growth factor binding protein-3 expression in intestinal epithelial cells. J Pediatr Gastroenterol Nutr 42: 134-141, 2006.
69. Wong JMW, Souza R, Kendall CWC, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 40: 235-243, 2006.
70. Wood SR, Zhao Q, Smith LH, Daniels CK. Altered morphology in cultured rat intestinal epithelial IEC-6 cells is associated with alkaline phosphatase expression. Tissue Cell 35: 47-58, 2003.
71. Xia CQ, Liu N, Yang D, Miwa G, Gan LS. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 33: 637-643, 2005.
72. Xiao JJ, Huang Y, Dai Z, Sadée W, Chen J, Liu S, et al. Chemoresistance to depsipeptide FK228 [(E) (1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21- diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16- ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 314: 467-475, 2005.
73. Yin L, Castagnino P, Assoian RK. ABCG2 expression and side population abundance regulated by a transforming growth factor betadirected epithelial-mesenchymal transition. Cancer Res 68: 800-807, 2008.
74. Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, et al. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge. Curr Drug Metab 8: 325-340, 2007.